|Sean McCarthy, D. Phil.|
President and Chief Executive Officer
Dr. McCarthy joined CytomX in 2010 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now part of Merck) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of large pharma partnerships as Vice President Business Development prior to the acquisition of the company by Lilly. Immediately before joining CytomX Dr. McCarthy was a transactional partner at venture capital firm Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including Afferent Pharmaceuticals (acquired by Merck), TyRx (acquired by Medtronic), Lumena (acquired by Shire), CoLucid (acquired by Lilly) and LEAD Therapeutics, the originator of talazoparib, now a Phase 3 product candidate in the Pfizer pipeline. Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. He received his B.Sc. in biochemistry and pharmacology at King’s College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy is a Board member of the California Life Sciences Association.
|W. Michael Kavanaugh, M.D.|
Chief Scientific Officer and Head of Research and Non-Clinical Development
Michael Kavanaugh, M.D. joined CytomX in January 2015 as chief scientific officer and head of research and early development. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis in 2006 as part of the company’s acquisition of the Chiron Corporation, where he was vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of medicine at UCSF.
|Rachel Humphrey, M.D.|
Chief Medical Officer
Rachel Humphrey, M.D., joined CytomX in August 2015. Dr. Humphrey recently held positions as vice president and head of immuno-oncology both at Eli Lilly and at AstraZeneca, where she was responsible for building the immuno-oncology departments and supervising the strategies and designs for all immuno-oncology agents in development. She previously served as vice president of product development at Bristol-Myers Squibb, where she led all aspects of clinical development of the antibody therapy Yervoy™ through the submission of global biologics license applications and global launch. At Bayer, Dr. Humphrey supervised all aspects of the early and late stage clinical development of Nexavar for treatment of renal cell carcinoma. She began her career as an oncology fellow and staff physician at the National Cancer Institute. Dr. Humphrey trained in internal medicine at the Johns Hopkins Hospital, received her medical degree from Case Western Reserve University and her bachelor’s degree from Harvard University.
Chief Financial Officer and Head of Corporate Development
|Debanjan Ray joined CytomX in 2011, and serves as chief financial officer and head of corporate development. He previously led partnering activities at CytomX, structuring and executing collaborations with AbbVie, BMS, Immunogen, and Pfizer that have resulted in more than $300 million in upfront and milestone payments to date and total potential deal value in excess of $5 billion. He has 15 years of experience in the biotechnology industry, including strategic consulting, venture capital and business development. Prior to joining CytomX, Mr. Ray was vice president of business development at Itero Biopharmaceuticals, where he helped drive several collaborations, including the company’s partnership on its lead product with Watson Pharmaceuticals. Prior to Itero, Mr. Ray was an associate director of business development at Portola Pharmaceuticals and an associate in the life sciences venture practice at J.P. Morgan Partners. He also served as a business analyst in the healthcare practice at McKinsey & Company. Mr. Ray holds a dual B.S. in chemical engineering and biology from the Massachusetts Institute of Technology and an M.B.A. from The Wharton School, University of Pennsylvania.|
|Cynthia J. Ladd|
Senior Vice President, General Counsel
|Cynthia Ladd joined CytomX in 2015 as senior vice president and general counsel. She most recently was an independent consultant to biotechnology companies, supporting corporate growth by advising on corporate strategy, negotiations around collaborations, and clinical and regulatory issues, as well as acting as general counsel. Previously, she was president and chief executive officer of AGY Therapeutics, leading the company through a successful venture round and its transition to a clinical organization. Ms. Ladd also served as senior vice president and general counsel at Pharmacyclics, where she led various operating groups, including regulatory affairs, advised on corporate governance and compliance, structured negotiations for business development activities and led all of the legal activities, including those related to the company’s intellectual property portfolio. Earlier in her career, Ms. Ladd held a number of positions at Genentech, including vice president of corporate law and chief corporate counsel. She began her career as an associate with Wilson, Sonsini, Goodrich & Rosati and Ware & Freidenrich (now DLA Piper). Ms. Ladd received her law degree from Stanford Law School, a master’s degree in animal nutrition and biochemistry from Cornell University and a bachelor’s degree in animal science from Pennsylvania State University.|